Abstract:e20007 Background: Everolimus, an oral mTOR inhibitor, has shown minimal activity as a single agent in patients with metastatic melanoma, unselected by potential predictive biomarkers (J Clin Oncol 24:463s, 2006). Selection of patients with melanoma harboring mTOR mutations may improve the efficiency of mTOR inhibitor in patients with melanoma (J Clin Oncol. 2012, 30(4):e37-40). This study (NCT01960829) aims to observe the efficacy of mTOR inhibitor in melanoma patients with mTOR mutations. Methods: Pts, who had unresectable melanoma harboring mutation in mTOR, who had measureable disease by RECIST, and who failed to systemic treatment (at lease 1), were enrolled. Pts received everolimus 10 mg daily continually until disease progression or unacceptable toxicity occurred. Response assessments were performed every 8 weeks. The endpoints were progression-free survival (PFS) and overall survival. Results: Of 396 pts screened, 10.3% had a mTOR mutation: 22/207(10.6%) acral, 15/104 (14.4%) mucosal, 2/28(7.1%) CSD and 3/57(5.2%) Non-CSD. Thus far, 8 pts have been treated, with 6 pts currently evaluable for response. The median age was 54 yrs (range: 38-65); the male:female ratio was 3:5; the median number of prior therapies was 2 (range: 1-4). 6 pts achieved stable diseases. The PFS were: 26 weeks+ (Exon 41: G5741C; acral melanoma; failed to DTIC, DDP and PTX), 18 weeks+ (Exon 41: A5794G; mucosal melanoma; failed to TMZ, bevacizumab, DDP and nab-PTX), 17 weeks+ (Exon 41: G1914R; acral melanoma; failed to DTIC), 12 weeks+ (Exon 46: C6520T; acral melanoma; failed to TMZ, carboplatin, bevacizumab, PTX and fotemustine), 11 weeks+ (Exon 47: C6637T; mucosal melanoma; failed to nab-PTX, DDP and TMZ) and 10 weeks+ (Exon 43: C6026T; CSD melanoma; failed to DTIC, DDP, bevacizumab and PTX). All the 6 pts showed median tumor shrinkage (12%, 10%, 9%, 23%, 1% and 5% respectively). Conclusions: While mTOR inhibitors show limited activity in a non-selected melanoma pt population, a substantial proportion of melanoma pts harboring mTOR mutation appear to respond. It may be expectable to identify appropriate pts prospectively for treatment with mTOR inhibitors. Clinical trial information: NCT01960829.

Analysis of Mtor Gene Aberrations in Melanoma Patients and Evaluation of Their Sensitivity to Pi3k-Akt-Mtor Pathway Inhibitors

Analysis of Mtor Mutations in Chinese Melanoma Patients and Evaluation of Their Sensitivity to PI3K-AKT-mTOR Pathway Inhibitors.

Mtorc1/autophagy-Regulated MerTK in Mutant BRAFV600 Melanoma with Acquired Resistance to BRAF Inhibition

Association of the Activation of the Mtor Pathway with Prognosis in Chinese Melanoma Patients.

PI3K/AKT/mTOR pathway inhibitors inhibit the growth of melanoma cells with mTOR H2189Y mutations in vitro.

Supplementary Figure S2 from Analysis of Mtor Gene Aberrations in Melanoma Patients and Evaluation of Their Sensitivity to PI3K–AKT–mTOR Pathway Inhibitors

Supplementary Table S6 from Analysis of <i>mtor</i> Gene Aberrations in Melanoma Patients and Evaluation of Their Sensitivity to PI3K–AKT–mTOR Pathway Inhibitors

P1.03-33 Mutational Spectrum and Prognosis of Non-Small-Cell Lung Cancer Harboring MTOR Mutations in Chinese Population

Mtor Pathway Activation in Kit-Mutated Melanoma with Acquired Imatinib Resistance.

Analysis of TSC1 Mutation Spectrum in Mucosal Melanoma

A Diverse Array of Cancer-Associated MTOR Mutations Are Hyperactivating and Can Predict Rapamycin Sensitivity.

A Phase II Study of Everolimus for Advanced Melanoma Patients with Mtor Mutations.

MAPK Pathway and TERT Promoter Gene Mutation Pattern and Its Prognostic Value in Melanoma Patients: A Retrospective Study of 2,793 Cases

Supplementary Figure S1 from Analysis of <i>mtor</i> Gene Aberrations in Melanoma Patients and Evaluation of Their Sensitivity to PI3K–AKT–mTOR Pathway Inhibitors

A Subset of Metastatic Pancreatic Ductal Adenocarcinomas Depends Quantitatively on Oncogenic Kras/Mek/Erk-Induced Hyperactive Mtor Signalling

Roles of mTOR and p-mTOR in gastrointestinal stromal tumors.

RPTOR Mutation: a Novel Predictor of Efficacious Immunotherapy in Melanoma

Analysis of NRAS Gain in 657 Patients with Melanoma and Evaluation of Its Sensitivity to a MEK Inhibitor.

Diverse mechanisms activate the PI 3-kinase/mTOR pathway in melanomas: implications for the use of PI 3-kinase inhibitors to overcome resistance to inhibitors of BRAF and MEK

Mutational Landscape of PI3K-AKT-mTOR Pathway in Breast Cancer: Implications for Targeted Therapeutics

Activation of mammalian target of rapamycin pathway confers adverse outcome in nonsmall cell lung carcinoma.